On the heels of a data readout suggesting one of its cancer drugs could become a future blockbuster, Zymeworks is adopting a ...

The deal gives J&J access to a pipeline of drugs designed to “hold and kill” tumors, led by a prostate cancer medicine that’s ...

Clinical trials are more connected and more closely examined than ever. Inspection readiness isn’t a last-minute document ...

Artios Pharma, which looking for newer targets that, like PARP inhibitors, affect the way tumors fix themselves, said its ...

Elevidys now has a “boxed” warning and is no longer available for Duchenne patients who can’t walk. Elsewhere, Nuvalent and Zymeworks unveiled data for targeted cancer drugs.

The new fund will mostly support biotechs making new drugs, with investments spanning from initial financings to follow-on ...

The deal, one of two multibillion-dollar buyouts from Merck this year, centers around a drug that could become an alternative ...

The “plausible mechanism” pathway, outlined by Martin Makary and Vinay Prasad, is designed to help accelerate treatments ...

Milvexian’s failure in acute coronary syndrome dampens the outlook for other anticoagulants like it and is the latest in a ...

Korro’s lead program for alpha-1 antitrypsin deficiency wasn’t as potent as anticipated, leading the company to change course ...

The appointment of Pazdur as CDER head comes shortly after the surprise ousting of George Tidmarsh and should quiet many of ...

A closely watched trial in Chinese patients is raising hope that ivonescimab will outperform Keytruda in a large global study that could reshape first-line treatment regimens.